Skip to content
Jubilant Ingrevia logo

Jubilant Ingrevia

JUBLINGREA NSE
₹561.75 −1.95 (−0.35%)
P/E
29.00
View as Markdown
MCP
Close 4 Nov 2026 ₹561.75 −102.65 −15.5% 1Y
Start ₹664.40

Key Fundamentals

MicrocapChemicals & PetrochemicalsChemicals

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
11.40%
Debt to Equity
0.25
EPS (TTM)
₹19.37
Book Value
₹208.22
Market Cap
—
P/E (TTM)
29.00
P/B
2.70
ROE
9.52%
Dividend Yield
0.89%
EBITDA
₹608 Cr
52W High
₹795.00
52W Low
₹537.30
Day Range
₹559.70 – ₹578.10
Volume
5,66,320

Peer Comparison

Commodities › Chemicals › Specialty Chemicals

Jubilant Ingrevia peer comparison
Pidilite Industries
₹1,510.2058.04₹1,54,107 Cr13.721.42%23.90%31.00%₹15,399 Cr₹2,677 Cr
Gujarat Fluorochemicals
₹4,613.3083.76₹49,073 Cr6.040.07%7.82%9.64%₹5,303 Cr₹600 Cr
Navin Fluorine International
₹8,785.0057.03₹44,060 Cr10.100.09%19.60%21.00%₹3,634 Cr₹789 Cr
Deepak Nitrite
₹1,578.4027.48₹20,919 Cr3.320.49%9.82%11.40%₹8,575 Cr₹784 Cr
Aether Industries
₹1,540.7086.90₹20,030 Cr7.880.00%9.66%11.90%₹1,231 Cr₹235 Cr
Aarti Industries
₹447.5530.57₹15,838 Cr2.590.23%7.13%6.86%₹9,010 Cr₹531 Cr
Atul
₹5,156.5019.67₹14,827 Cr2.310.59%11.50%14.90%₹6,969 Cr₹788 Cr
Jubilant Ingrevia (this company)
₹561.7529.00₹9,019 Cr2.700.89%9.52%11.40%₹4,651 Cr₹308 Cr
Median 8 companies₹1,559.5543.80₹20,474 Cr4.680.36%9.74%11.65%₹6,136 Cr₹692 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

52 Average

Data confidence 100/100

Category scores

Quality
58
Good
Returns, margins, earnings quality 22% weight
Valuation
54
Average
Cheap vs sector & own history 24% weight
Growth
42
Weak
Sales & profit trajectory 9% weight
Financial Health
52
Average
Solvency, leverage, coverage 9% weight
Momentum
17
Poor
Trend strength, vol-adjusted 12% weight
Ownership
72
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has been maintaining a healthy dividend payout of 34.4%
  • Company's working capital requirements have reduced from 29.4 days to 22.0 days

Weaknesses

4
  • Stock is trading at 3.20 times its book value
  • Company has a low return on equity of 8.49% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -6.25%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1243
OscillatorsBullish243
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
35.07
Neutral
MACD (12,26,9)
−21.91
Bearish
SMA (50)
639.40
Bearish
SMA (200)
658.09
Bearish

As of

Analyst Rating

Based on 6 analysts
BUY83%

5 of 6 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
5
83%
HOLD
1
17%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+45.02%
3Y−2.76%
1Y+5.03%
TTM+10.98%

Net profit

Net profit growth by window
5Y+38.78%
3Y−3.36%
1Y+10.76%
TTM+11.19%

Operating cash flow

Operating cash flow growth by window
5Y+36.15%
3Y+4.29%
1Y+3.15%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−4.17 pp
3Y+1.44 pp
1Y+0.52 pp
TTM+0.24 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹0.00 Cr
Mar 2021₹684 Cr
Mar 2022₹4,949 Cr
Mar 2023₹4,773 Cr
Mar 2024₹4,136 Cr
Mar 2025₹4,178 Cr
Mar 2026₹4,388 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹0.00 Cr
Mar 2021₹54.00 Cr
Mar 2022₹477 Cr
Mar 2023₹308 Cr
Mar 2024₹183 Cr
Mar 2025₹251 Cr
Mar 2026₹278 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹826 Cr +36.0% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 4 Aug 2026
AI opinion · based on fundamentals
Risk medium

Jubilant Ingrevia Ltd is a mid-cap specialty chemicals company with a market cap of ₹12,161 crore trading at a PE of 39.1x. FY26 consolidated revenue was ₹4,388 crore (up 5% YoY) with PAT of ₹278 crore (up 11% YoY), while the 3-year compounded sales and profit growth remain negative at -3% and -2% respectively, indicating a recent recovery from a subdued period.

Bull Case 8
  • Q4 FY26 revenue grew 12% YoY and EBITDA grew 11% YoY, marking the highest quarterly revenue and EBITDA in 14 quarters
  • Q4 FY26 PAT surged 153% YoY to approximately ₹74 crore, showing sharp profit recovery
  • FY26 full-year PAT grew 11% YoY to ₹278 crore, demonstrating consistent earnings improvement
  • EBITDA margin improved to 14.7% in Q4 FY25 from lower levels in prior quarters, with FY26 EBITDA at ₹607 crore (up 9% YoY)
  • Working capital days reduced from 29.4 days to 22.0 days, freeing up cash for operations and capex
  • Healthy dividend payout of 29.6% with total dividend of ₹5/share for FY25, signaling confidence in cash generation
  • TTM sales growth of 11% and TTM profit growth of 15% indicate an inflection from the negative 3-year CAGR period
  • 5-year compounded sales CAGR of 45% and profit CAGR of 35% reflect structural long-term revenue scale-up since demerger
Bear Case 7
  • 3-year compounded sales CAGR is -3% and profit CAGR is -2%, indicating a prolonged growth slump between FY22-FY25
  • PE of 39.1x is elevated for a chemicals company with only 8.48% 3-year average ROE, suggesting stretched valuations
  • Promoter holding has declined by 6.25% over the last 3 years, raising questions about insider confidence
  • Company may be capitalizing interest costs, which could overstate reported profits and asset values
  • 1-year stock CAGR of only 1% despite broader market gains suggests market skepticism about near-term earnings power
  • Q4 FY25 revenue of ₹1,051 crore was actually down 2% QoQ from ₹1,074 crore in Q4 FY24, showing uneven recovery
  • Dividend yield of only 0.66% provides minimal income cushion at current valuation levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

92d ago

TL;DR: Jubilant Ingrevia is delivering strong execution with 41% profit growth and 25% revenue growth in Q1FY27, driven by Fine Chemicals, CDMO, and Nutrition segments. No visible headwinds in recent news flow. The company maintained its ₹750-800 crore EBITDA guidance, signalling management confidence. The trend is clearly improving with broad-based segment strength and shareholder returns via dividends.

Positives 2
  • Q1 profit surges 41% YoY Jul 27

    Net profit rose 41% to ₹106 crore on revenue of ₹1,300 crore (up 25% YoY). EBITDA reached ₹209 crore at 16% margin with full-year guidance of ₹750-800 crore maintained.

  • ₹2.50 final dividend declared Aug 1

    Board recommended ₹2.50 per share final dividend for FY 2025-26, to be approved at AGM on August 26, 2026. Directors Shyam S. Bhartia and Priyavrat Bhartia proposed for re-appointment.

Neutral 3
  • 7th AGM scheduled Aug 26 Aug 2

    Jubilant Ingrevia will hold its 7th AGM via video conference on August 26, 2026, with voting on dividend and director re-appointments.

  • FY26 BRSR report filed Aug 1

    Company submitted its Business Responsibility and Sustainability Report for FY26 detailing ESG performance, safety metrics, and environmental targets.

  • Q1FY27 earnings call hosted Jul 13

    Investor conference call was held on July 23, 2026 to discuss unaudited financial results for the quarter ended June 30, 2026.

Quarterly Results

₹ Cr
JUBLINGREA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
1,075
1,020
966
1,074
1,024
1,045
1,057
1,051
1,038
1,121
1,051
1,179
1,300
1,394
Expenses
958
902
871
983
915
921
918
905
896
985
924
1,016
1,101
1,182
Operating Profit
117
118
96
91
110
124
138
147
142
135
126
163
199
—
OPM %
11%
12%
10%
8%
11%
12%
13%
14%
14%
12%
12%
14%
15%
—
Other Income
8
9
9
10
10
10
9
8
11
11
−4
9
10
9
Interest
11
13
15
14
14
15
12
14
13
12
12
12
17
23
Depreciation
32
34
34
36
39
40
40
39
41
41
45
48
51
51
PBT
81
80
55
51
66
80
96
102
100
93
65
112
141
148
Tax %
29%
28%
30%
43%
26%
26%
27%
27%
25%
25%
28%
23%
25%
25%
Net Profit
58
57
39
29
49
59
69
74
75
69
47
86
106
111
EPS (₹)
3.62
3.61
2.42
1.84
3.06
3.7
4.36
4.65
4.71
4.36
2.94
5.43
6.64
—

Sep 2026: from the results filed on 27 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
JUBLINGREA profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
684
4,949
4,773
4,136
4,178
4,388
4,651
Expenses
0
567
4,108
4,224
3,708
3,658
3,820
4,027
Operating Profit
0
117
841
549
427
519
568
624
OPM %
—
17%
17%
11%
10%
12%
13%
13%
Other Income
0
−10
22
32
29
38
27
27
Interest
0
7
31
22
53
56
49
54
Depreciation
0
22
123
122
136
158
175
186
PBT
0
77
709
437
268
344
370
411
Tax %
0%
30%
33%
30%
32%
27%
25%
—
Net Profit
0
54
477
308
183
251
278
309
EPS (₹)
−3.4
3.41
29.93
19.31
11.48
15.77
17.45
19.37
Div. Payout %
0%
10%
17%
26%
43%
31%
28%
—

Balance Sheet

₹ Cr
JUBLINGREA balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.05
16
16
16
16
16
16
Reserves
0
1,907
2,417
2,650
2,722
2,911
3,110
Borrowings
0
556
238
407
740
764
792
Other Liabilities
0
888
1,111
1,176
1,241
1,324
1,551
Total Liabilities
0
3,366
3,782
4,249
4,719
5,015
5,470
Fixed Assets
0
1,805
1,798
1,846
2,539
2,581
3,183
CWIP
0
65
174
525
331
525
154
Investments
0
50
6
8
15
37
33
Other Assets
0
1,446
1,804
1,870
1,834
1,872
2,099
Total Assets
0
3,366
3,782
4,249
4,719
5,015
5,470

Cash Flow

₹ Cr
JUBLINGREA cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
112
453
462
430
508
524
Investing
0
33
−71
−469
−568
−389
−250
Financing
0
−72
−418
42
144
−129
−155
Net Cash Flow
0
73
−36
35
6
−9
119
Free Cash Flow
0
85
225
−16
−136
156
235
CFO/OP
0
106
69
98
111
113
111

Ratios

JUBLINGREA financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
251
43
39
50
53
65
Inventory Days
—
601
117
146
160
163
140
Days Payable
—
685
103
113
131
141
150
Cash Conversion Cycle
—
167
57
72
80
75
55
Working Capital Days
—
220
49
42
37
29
22
ROCE %
—
8%
29%
16%
10%
11%
11%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jubilant Ingrevia insights

64 extracted metrics across FY20–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 45.22%
  • DIIs 25.17%
  • Public 21.69%
  • FIIs 6.94%
  • Government 0.02%

9.11% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Jubilant Ingrevia

What does Jubilant Ingrevia Ltd do?
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality…
Where is Jubilant Ingrevia Ltd (JUBLINGREA) listed?
Jubilant Ingrevia Ltd trades as JUBLINGREA on the NSE and under code 543271 on the BSE.
Which sector does Jubilant Ingrevia Ltd belong to?
Jubilant Ingrevia Ltd is classified under the Chemicals sector, in the Specialty Chemicals industry.
What is the PE ratio of Jubilant Ingrevia Ltd?
Jubilant Ingrevia Ltd trades at a PE ratio of 29.00 as of 4 Nov 2026, on earnings per share of ₹19.37, against a book value of ₹208.22 per share.
What is the 52-week high and low of Jubilant Ingrevia Ltd?
Over the last 52 weeks Jubilant Ingrevia Ltd has traded between ₹537.3 and ₹795 as of 4 Nov 2026.
Does Jubilant Ingrevia Ltd pay dividends?
Jubilant Ingrevia Ltd has a dividend yield of 0.89%.
What is the Return on Equity (ROE) of Jubilant Ingrevia Ltd?
Jubilant Ingrevia Ltd reported a return on equity of 9.52%. Its debt-to-equity ratio is 0.25.

Company Information

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards. Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Website jubilantingrevia.com
Listed 19 Mar 2021
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JUBLINGREA.md for Jubilant Ingrevia Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Chemical & Petrochemical stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month